Cohance Lifesciences Limited

BSE: COHANCE543064ISIN INE03QK01018

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹438.05-2.30 (-0.52%)

as of 18 Sep 2026

52W high: ₹932.65
52W low: ₹267.85
Off 52W high: -53.03%
1M return: -2.13%
3M return: +7.96%
6M return: +46.38%
1Y return: -52.08%
20D avg volume: 2,87,040
50 DMA: ₹443.65
200 DMA: ₹421.44

Key ratios Consolidated

Market cap: ₹16,760 Cr
Current price: ₹438.05
52W high / low: ₹932.65 / ₹267.85
Face value: ₹1.00
P/E: 286.32
P/B: —
EPS (TTM): ₹1.53
Book value / share: —
ROE: —
ROCE: 4.80%
Operating margin: —
Net margin: —
Debt / equity: 0.04
Net debt: ₹120.53 Cr
Interest cover: 6.56
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 154.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	422.26	619.12	544.55	555.57	549.31	402.02	307.15	257.72	230.69	252.93	219.82	231.05
	12.25	1.84	6.16	15.60	14.17	10.57	15.71	14.12	18.16	17.05	14.35	19.84
	477.38	580.86	505.25	487.40	492.62	360.99	213.13	172.34	165.77	199.13	168.70	145.49
	158.68	138.96	196.50	191.60	178.33	70.24	67.04	47.08	38.30	71.42	63.53	51.16
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	132.96	128.99	118.68	126.72	133.32	89.08	63.29	51.87	45.62	39.39	32.83	28.58
	6.74	9.19	9.11	8.76	10.18	5.75	3.33	1.67	1.60	2.30	1.27	0.50
	49.54	51.23	46.94	44.02	45.14	26.78	20.35	16.96	13.40	17.25	12.75	11.89
	167.86	177.00	171.61	166.77	155.84	105.38	70.53	49.78	14.46	19.94	14.42	13.16
	-42.87	36.42	45.46	83.77	70.86	51.60	109.73	99.50	83.08	70.85	65.47	105.41
	0.00	-16.51	-4.86	0.00	-8.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	-42.87	19.91	40.60	83.77	62.76	51.60	109.73	99.50	83.08	70.85	65.47	105.41
	2.32	11.60	11.58	17.38	16.36	12.87	26.44	17.52	22.32	17.48	18.71	25.84
	-45.19	8.31	29.02	66.39	46.40	38.73	83.29	81.98	60.76	53.37	46.75	79.56
	-0.63	0.51	0.96	1.94	1.28	1.65	3.26	3.23	2.39	2.10	1.84	3.13
Key metrics
	13.41	80.33	96.65	136.55	118.08	84.13	133.41	118.13	98.08	90.40	79.49	117.80
	3.20%	13.00%	17.70%	24.60%	21.50%	20.90%	43.40%	45.80%	42.50%	35.70%	36.20%	51.00%
	-10.70%	1.30%	5.30%	11.90%	8.40%	9.60%	27.10%	31.80%	26.30%	21.10%	21.30%	34.40%
	—	0.60%	—	1.90%	—	2.20%	—	—	—	—	—	—
	-23.10%	54.00%	77.30%	115.60%	138.10%	58.90%	39.70%	11.50%	—	—	—	—
	-197.40%	-78.50%	-65.20%	-19.00%	-23.60%	-27.40%	78.20%	3.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20
Income statement
	2,142	2,269	1,198	1,051	1,340	1,320	1,010	833.79
	35.85	34.09	58.56	61.91	46.36	92.38	14.24	18.12
	2,051	2,066	912.22	707.59	826.96	786.12	610.02	495.61
	685.74	705.39	222.66	265.88	430.08	459.46	310.31	240.24
	0.00	0.00	0.00	—	—	—	—	—
	507.35	507.71	249.56	135.92	110.51	100.48	76.23	73.72
	33.80	37.24	12.35	7.45	5.44	6.23	9.14	23.07
	191.73	187.33	77.49	54.60	47.73	39.10	31.64	23.86
	683.24	671.22	267.53	61.11	69.28	—	46.22	40.02
	122.78	236.51	343.92	405.67	559.73	626.48	413.94	356.30
	-21.37	-29.47	0.00	0.00	0.00	0.00	0.00	0.00
	101.41	207.04	343.92	405.67	559.73	626.48	413.94	356.30
	42.88	56.92	79.15	105.39	148.44	213.78	105.33	87.51
	58.53	150.12	264.77	300.28	411.29	453.81	362.34	317.00
	2.78	4.69	10.52	11.80	16.16	17.83	14.23	24.91
Key metrics
	326.94	431.61	433.76	467.72	612.90	671.81	454.72	403.23
	15.27%	19.00%	36.20%	44.50%	45.70%	50.90%	45.00%	48.40%
	2.73%	6.60%	22.10%	28.60%	30.70%	34.40%	35.90%	38.00%
	—	4.80%	13.40%	—	—	—	—	—
	—	89.40%	13.90%	-21.60%	1.50%	30.80%	21.10%	—
	—	-43.30%	-11.80%	-27.00%	-9.40%	25.20%	14.30%	—
	—	148.44	132.45	—	—	—	—	—
	—	2.45	1.09	—	—	—	—	—
	—	0.04	0.04	—	—	—	—	—
	—	120.53	-7.27	—	—	—	—	—
	—	154.3	113.1	—	—	—	—	—
Balance sheet
	—	5,730	3,032	—	—	—	—	—
	—	1,796	853.28	—	—	—	—	—
	—	49.14	85.40	—	—	—	—	—
	—	681.01	284.44	—	—	—	—	—
	—	562.23	166.57	—	—	—	—	—
	—	217.17	111.47	—	—	—	—	—
	—	1,990	995.20	—	—	—	—	—
	—	284.58	80.21	—	—	—	—	—
	—	645.93	365.19	—	—	—	—	—
	—	169.67	78.13	—	—	—	—	—
	—	119.19	71.89	—	—	—	—	—
	—	50.48	6.24	—	—	—	—	—
	—	4,034	1,841	—	—	—	—	—
Cash flow
	—	368.32	288.16	—	—	—	—	—
	—	-254.57	-255.30	—	—	—	—	—
	—	-165.15	3.32	—	—	—	—	—
	—	219.88	155.71	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	359.89	567.55	481.58	497.79	483.58	330.17	275.39	236.06	222.09	243.52	212.83	224.62
	12.16	-0.79	6.12	26.30	13.10	6.63	15.18	13.43	17.95	16.87	13.97	14.20
	369.84	493.81	417.41	403.37	417.54	280.48	175.97	148.81	152.65	189.33	157.29	138.25
	151.90	134.63	193.29	188.19	175.16	66.98	55.11	39.17	34.73	63.16	60.65	46.95
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	96.34	96.81	85.09	95.10	103.43	52.72	50.34	44.25	43.17	37.10	30.62	26.51
	2.12	5.17	5.25	5.24	6.80	2.30	2.60	1.47	1.60	2.29	1.27	0.50
	34.32	37.66	33.36	31.20	31.36	15.19	13.44	12.29	12.00	15.66	11.33	10.48
	126.49	142.78	136.78	133.45	129.96	79.64	62.45	44.79	13.73	19.07	13.57	12.58
	2.21	72.95	70.29	120.72	79.14	56.32	114.60	100.68	87.39	71.06	69.50	100.57
	0.00	-16.51	-4.86	0.00	-8.10	0.00	—	—	—	—	—	—
	2.21	56.44	65.43	120.72	71.04	56.32	114.60	100.68	87.39	71.06	69.50	100.57
	0.80	21.88	18.14	26.43	18.47	11.98	28.25	24.35	22.32	17.62	17.14	25.84
	1.41	34.56	47.29	94.29	52.57	44.34	86.35	76.33	65.08	53.43	52.36	74.73
	0.04	0.90	1.24	2.46	1.38	1.74	3.39	3.00	2.56	2.10	2.06	2.94
Key metrics
	38.65	99.27	104.04	157.16	109.20	73.81	130.64	114.44	100.99	89.01	82.10	111.55
	10.70%	17.50%	21.60%	31.60%	22.60%	22.40%	47.40%	48.50%	45.50%	36.60%	38.60%	49.70%
	0.40%	6.10%	9.80%	18.90%	10.90%	13.40%	31.40%	32.30%	29.30%	21.90%	24.60%	33.30%
	—	1.30%	—	2.80%	—	2.50%	—	—	—	—	—	—
	-25.60%	71.90%	74.90%	110.90%	117.70%	35.60%	29.40%	5.10%	—	—	—	—
	-97.30%	-22.10%	-45.20%	23.50%	-19.20%	-17.00%	64.90%	2.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20
Income statement
	1,907	2,030	1,094	1,025	1,330	1,320	1,010	833.79
	43.79	44.73	53.98	55.09	44.55	187.79	14.24	18.12
	1,684	1,732	796.14	671.31	795.24	785.56	609.98	494.32
	668.01	691.27	212.51	248.38	421.36	459.46	310.31	240.24
	0.00	0.00	0.00	—	—	—	—	—
	373.34	380.43	198.30	126.88	100.84	100.48	76.23	73.72
	17.78	22.46	8.00	7.43	5.39	6.23	9.14	21.81
	136.54	133.58	57.20	48.79	42.84	39.10	31.64	23.86
	539.50	542.97	233.60	58.17	66.28	57.10	46.17	39.98
	266.17	343.10	351.35	408.77	579.39	722.45	413.98	357.59
	-21.37	-29.47	0.00	—	—	—	—	—
	244.80	313.63	351.35	408.77	579.39	722.45	413.98	357.59
	67.25	84.92	79.64	103.96	146.79	164.35	105.33	87.51
	177.55	228.71	271.71	304.82	432.60	558.10	308.65	270.08
	4.64	5.98	10.67	11.97	16.99	21.92	12.12	21.22
Key metrics
	399.12	469.67	416.55	464.99	627.62	767.78	454.76	403.26
	20.93%	23.10%	38.10%	45.40%	47.20%	58.20%	45.00%	48.40%
	9.31%	11.30%	24.80%	29.70%	32.50%	42.30%	30.60%	32.40%
	—	7.30%	15.10%	—	—	—	—	—
	—	85.70%	6.70%	-22.90%	0.70%	30.80%	21.10%	—
	—	-15.80%	-10.90%	-29.50%	-22.50%	80.80%	14.30%	—
	—	221.33	162.13	—	—	—	—	—
	—	1.70	1.11	—	—	—	—	—
	—	0.02	0.03	—	—	—	—	—
	—	82.13	50.64	—	—	—	—	—
	—	165.6	108.6	—	—	—	—	—
Balance sheet
	—	5,113	2,588	—	—	—	—	—
	—	1,669	708.76	—	—	—	—	—
	—	13.11	19.36	—	—	—	—	—
	—	641.61	242.47	—	—	—	—	—
	—	540.13	154.12	—	—	—	—	—
	—	194.84	97.17	—	—	—	—	—
	—	1,608	623.44	—	—	—	—	—
	—	260.15	71.03	—	—	—	—	—
	—	504.71	213.53	—	—	—	—	—
	—	95.24	70.00	—	—	—	—	—
	—	44.76	70.00	—	—	—	—	—
	—	50.48	0.00	—	—	—	—	—
	—	4,480	2,316	—	—	—	—	—
Cash flow
	—	389.57	301.03	—	—	—	—	—
	—	-204.29	-320.94	—	—	—	—	—
	—	-202.78	20.81	—	—	—	—	—
	—	168.24	138.90	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +15.14%
Sales CAGR 5Y: +15.00%
Sales CAGR 10Y: —
Profit CAGR 3Y: -19.14%
Profit CAGR 5Y: -5.82%
Profit CAGR 10Y: —
Sales YoY (TTM): +43.89%
Profit YoY (TTM): -31.60%

Consolidated

Sales CAGR 3Y: +19.17%
Sales CAGR 5Y: +17.57%
Sales CAGR 10Y: —
Profit CAGR 3Y: -28.53%
Profit CAGR 5Y: -16.16%
Profit CAGR 10Y: —
Sales YoY (TTM): +41.24%
Profit YoY (TTM): -76.63%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 57.49%

Holder	Type	Holding	Previous	Change
BEHRYANDA LIMITED	Promoter	33.34%	—	—
JUSMIRIAL HOLDINGS LIMITED	Promoter	24.15%	—	—
DSP REGULAR SAVINGS FUND	Public	4.28%	—	—
ICIC PREDUENTIAL HEALTH CARE AND DIAGANOSTIC	Public	4.19%	—	—
JASUB PROPERTY HOLDINGS LLP	Public	3.84%	—	—
SBI MNC FUND	Public	3.33%	—	—
JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED	Public	2.51%	—	—
HDFC TRUSTEE COMPANY LIMITED - HDFC TAX SAVER FUND	Public	2.16%	—	—
SBI LIFE INSURANCE CO. LTD	Public	1.75%	—	—
INVESCO INDIA CONTRA FUND	Public	1.69%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

General update18 Sep 2026 · Company Update / General
Scrutinizer`s report17 Sep 2026 · AGM/EGM / AGM
Proceedings of Annual General Meeting17 Sep 2026 · AGM/EGM / AGM
Investor Meet17 Sep 2026 · Company Update / Analyst / Investor Meet
Completion of USFDA Inspection5 Sep 2026 · Company Update / General
Press Release3 Sep 2026 · Company Update / Press Release / Media Release
Outcome of Committee Meeting3 Sep 2026 · Others / Outcome without intimation
Investors Meet27 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication27 Aug 2026 · Company Update / Newspaper Publication
BRSR26 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report 202626 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of AGM 202626 Aug 2026 · AGM/EGM / AGM
Credit Rating13 Aug 2026 · Company Update / Credit Rating
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd12 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Earnings Call Transcript11 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication6 Aug 2026 · Company Update / Newspaper Publication
Con Call audio link5 Aug 2026 · Company Update / Analyst / Investor Meet
Completion of USFDA Inspection5 Aug 2026 · Company Update / General
Outcome of the Board Meeting5 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting5 Aug 2026 · Board Meeting / Outcome of Board Meeting
Allotment of Equity Shares pursuant to exercise of Stock Options and grant of Stock Options to certain eligible employees of the Company23 Jul 2026 · Company Update / General
Results Conference Call23 Jul 2026 · Company Update / Analyst / Investor Meet
Cohance Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....23 Jul 2026 · Board Meeting / Board Meeting
Compliance Certificate under 74(5) of SEBI (DP) Regulations 20187 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication26 Jun 2026 · Company Update / Newspaper Publication
Clarification on Volume Movement24 Jun 2026 · Company Update / General
The Exchange has sought clarification from Cohance Lifesciences Ltd on June 24, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.24 Jun 2026 · Company Update / Clarification
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd19 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CSC Global Capital Markets (Singapore) Pte Ltd19 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CSC Global Capital Markets (Singapore) Pte Ltd19 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June ....18 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 17, 2026 for Jusmiral Holdings Ltd & Others18 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 17, 2026 for Jusmiral Holdings Ltd & Others18 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Resignation of Mr. Himanshu Agarwal as Executive Director and Chief Financial Officer of the Company17 Jun 2026 · Company Update / Resignation of Director
Postal Ballot Scrutinizer''s Report14 Jun 2026 · AGM/EGM / Postal Ballot
Postal Ballot outcome and voting results14 Jun 2026 · AGM/EGM / Postal Ballot
Investors Meet2 Jun 2026 · Company Update / Analyst / Investor Meet
Annual Secretarial Compliance Report30 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Investors Meet25 May 2026 · Company Update / Analyst / Investor Meet

Board meetings

5 Aug 2026 Board Meeting - Financial Results